Indegene receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Indegene Ltd (INEG)
Track the Indegene share price today and view real-time INEG share price data, including charts, technicals, and key financials. View the INEG premarket stock price ahead of the market session or assess the after hours quote. Explore INEG stock price movements, trading volume, and market activity across the NSE exchange.
What Is the Indegene Stock Price Today?
The Indegene stock price today is 568.75.
What Is the Stock Symbol for Indegene?
The stock symbol for Indegene is ""INEG.""
What Stock Exchange Does Indegene Trade On?
Indegene is listed and trades on the NSE stock exchange.
Is Indegene a Good Stock to Buy?
Determining whether Indegene or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INEG quote. (ISIN: INE065X01017)
What Is the Indegene Stock Price Today?
The Indegene stock price today is 568.75.
What Is the Stock Symbol for Indegene?
The stock symbol for Indegene is ""INEG.""
What Stock Exchange Does Indegene Trade On?
Indegene is listed and trades on the NSE stock exchange.
Is Indegene a Good Stock to Buy?
Determining whether Indegene or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the INEG quote. (ISIN: INE065X01017)
568.75
+14.30(+2.58%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
556.20
574.95
52 wk Range
414.00
596.80
Unusual trading volume
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
556.20574.95
52 wk Range
414.00596.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.41%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.41%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
INEG Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
620.63
Upside
+9.12%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Prominent player in the Life Sciences Tools & Services industry
Indegene receives Investment Bank Analyst Rating Update- Investing.com
Pro
Indegene receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Indegene receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Indegene receives Investment Bank Analyst Rating Update- Investing.com
Pro
Indegene receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
6 Buy
2 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 620.63
(+9.12% Upside)
Indegene Ltd Earnings Call Summary for Q1/2027
- Indegene reported Q1 FY2027 revenue of INR 10,631M ($112.5M), up 39.7% YoY and 6% sequentially, marking strongest Q1 growth in four years.
- EBITDA margin fell to 16.9% vs. historical 19-20% range due to AI and workforce investments; management expects margin recovery by Q4 FY2027.
- Active customers expanded to 105 from 65 at listing; 60% of revenue now derived from output and outcome-based contracts vs. traditional staffing.
- Stock rose 2.78% to $529 following results; management guided for accelerating organic growth in H2 FY2027 with large deals ramping in Q3.
- CEO Gupta positioned Indegene as 'structurally different' category focused on pharma revenue-side budgets, embedding GenAI across platforms.
Last Updated: 31/07/2026, 03:46 pm
Read Full TranscriptEarnings
Latest Release
30/07/2026
EPS / Forecast
4.80 / 4.60
Revenue / Forecast
10.63B / 10.69B
Compare INEG to Peers and Sector
Metrics to compare | INEG | Sector Sector - Average of metrics from a broad group of related Industrials sector companies | Relationship RelationshipINEGPeersSector | |
|---|---|---|---|---|
P/E Ratio | 33.3x | 28.6x | −0.4x | |
PEG Ratio | −4.18 | 1.74 | 0.00 | |
Price/Book | 4.3x | 4.9x | 2.6x | |
Price / LTM Sales | 3.5x | 3.2x | 3.1x | |
Upside (Analyst Target) | 9.6% | 1.3% | 48.2% | |
Fair Value Upside | Unlock | 10.0% | 5.8% | Unlock |
Indegene Limited operates as a digital-first life sciences commercialization company in India, the United States, Europe, North America, and internationally. It operates through Enterprise Medical Solutions, Enterprise Commercial Solutions, and Other segments. The company provides AI-embedded commercialization services for biopharmaceutical, emerging biotech, and medical devices companies. It also offers enterprise commercial, medical, and clinical solutions; and omnichannel activation solutions. In addition, the company operates NEXT technology platforms, as well as provides analytics, technology, commercial, medical, regulatory, and safety services to life science and healthcare organizations. Further, it engages in the professional, and scientific and technical activities. Indegene Limited was incorporated in 1998 and is based in Bengaluru, India.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Indegene (INEG) Stock Price Today?
The Indegene stock price today is 568.75 INR.
What Stock Exchange Does Indegene Trade On?
Indegene is listed and trades on the India National Stock Exchange.
What Is the Stock Symbol for Indegene?
The stock symbol for Indegene is "INEG."
Does Indegene Pay Dividends? What’s The Current Dividend Yield?
The Indegene dividend yield is 0.41%.
What Is the Indegene Market Cap?
As of today, Indegene market cap is 137.01B INR.
What Is Indegene's Earnings Per Share (TTM)?
The Indegene EPS (TTM) is 16.61.
When Is the Next Indegene Earnings Date?
Indegene will release its next earnings report on 04/11/2026.
From a Technical Analysis Perspective, Is INEG a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Indegene Stock Split?
Indegene has split 0 times.
How Many Employees Does Indegene Have?
Indegene has 4687 employees.
What is the current trading status of Indegene (INEG)?
As of 11/08/2026, Indegene (INEG) is trading at a price of 568.75 INR, with a previous close of 568.75 INR. The stock has fluctuated within a day range of 556.20 INR to 574.95 INR, while its 52-week range spans from 414.00 INR to 596.80 INR.
What Is Indegene (INEG) Price Target According to Analysts?
The average 12-month price target for Indegene is 620.63 INR, with a high estimate of 735 INR and a low estimate of 500 INR. 6 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +9.12% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.